TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers, has announced the publication of a peer-reviewed article in the journal Cancers reporting preclinical results for its lead therapeutic candidate, TTX-MC138, in a model of breast cancer bone metastasis. The study demonstrated that TTX-MC138 accumulated in metastatic bone lesions following systemic administration, reduced expression of microRNA-10b (miR-10b), increased expression of the downstream tumor-suppressor target HOXD10, and produced significant survival benefits compared with controls. Repeated dosing was well tolerated with no observed systemic toxicity.
These findings further support TransCode's approach of inhibiting miR-10b using its proprietary oligonucleotide nanotechnology and suggest potential applicability across additional metastatic disease settings. The results are particularly significant because bone metastasis is a common and serious complication of advanced breast cancer, often leading to skeletal-related events and reduced quality of life. Current treatment options for metastatic disease are limited, and there is a high unmet need for therapies that can specifically target the mechanisms driving metastasis.
For the full press release, visit https://ibn.fm/E6gbq.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
This announcement underscores the potential of RNA-based therapeutics in oncology, specifically in targeting metastasis, which is the cause of most cancer-related deaths. By demonstrating survival benefits in a preclinical model, TransCode provides evidence that its approach could eventually lead to new treatment options for patients with metastatic breast cancer and possibly other cancers that spread to bones.
The findings also highlight the importance of microRNA-10b as a therapeutic target. Overexpression of miR-10b has been associated with metastasis in various cancers, making it a promising target for intervention. If these results translate to clinical settings, TTX-MC138 could become a significant addition to the arsenal against advanced cancers.
Investors and industry observers will be watching for further developments from TransCode as it progresses TTX-MC138 through the pipeline. The positive preclinical data may also bolster confidence in the company's broader platform and its ability to address high-risk cancers.
For more information on BioMedWire and its services, visit https://www.BioMedWire.com.
